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Cardiovascular diseases (CVDs), including atherosclerosis, are globally the leading cause
of death. Key factors contributing to onset and progression of atherosclerosis include
the pro-inflammatory cytokines Interferon (IFN)α and IFNγ and the Pattern Recognition
Receptor (PRR) Toll-like receptor 4 (TLR4). Together, they trigger activation of Signal
Transducer and Activator of Transcription (STAT)s. Searches for compounds targeting the
pTyr-SH2 interaction area of STAT3, yielded many small molecules, including STATTIC
and STX-0119. However, many of these inhibitors do not seem STAT3-specific. We
hypothesized that multi-STAT-inhibitors that simultaneously block STAT1, STAT2, and
STAT3 activity and pro-inflammatory target gene expression may be a promising strategy
to treat CVDs. Using comparative in silico docking of multiple STAT-SH2 models on
multi-million compound libraries, we identified the novel multi-STAT inhibitor, C01L_F03.
This compound targets the SH2 domain of STAT1, STAT2, and STAT3 with the same
affinity and simultaneously blocks their activity and expression of multiple STAT-target
genes in HMECs in response to IFNα. The same in silico and in vitromulti-STAT inhibiting
capacity was shown for STATTIC and STX-0119. Moreover, C01L_F03, STATTIC and
STX-0119 were also able to affect genome-wide interactions between IFNγ and TLR4
by commonly inhibiting pro-inflammatory and pro-atherogenic gene expression directed
by cooperative involvement of STATs with IRFs and/or NF-κB. Moreover, we observed
that multi-STAT inhibitors could be used to inhibit IFNγ+LPS-induced HMECs migration,
leukocyte adhesion to ECs as well as impairment of mesenteric artery contractility.
Together, this implicates that application of a multi-STAT inhibitory strategy could provide
great promise for the treatment of CVDs.
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INTRODUCTION
Cardiovascular diseases (CVDs) are globally the leading
cause of death in Western Countries. Atherosclerosis is
preceded by endothelial dysfunction, a prothrombotic and
pro-inflammatory state of the endothelium which involves the
increased expression of cell surface adhesion molecules, the
production of inflammatory cytokines and chemokines and
altered contractility of vascular smooth muscle cells (VSMCs)
(1). Blood leukocytes are recruited to the injured vascular
endothelium. This process is a hallmark of the initiation and
progression of atherosclerosis. Recruitment of blood leukocytes
involves many inflammatory mediators, modulated by cells
of both innate and adaptive immunity (1). Pro-inflammatory
cytokines Interferon (IFN)α, IFNγ and Toll-like receptor 4
(TLR4) activators are key factors contributing to early stages
of atherosclerosis (2). IFNα and IFNγ induce phosphorylation
of STATs through Janus-kinases (JAK)s. Thus, IFNα stimulates
formation of STAT1 and STAT2 heterodimers, that complexed
with IRF9 form ISGF3 and regulate expression of ISRE-
containing genes. On the other hand, IFNα and IFNγ activate
STAT1 or STAT3 homo-/heterodimer formation, which regulate
expression of a distinct set of GAS-driven genes. IFNs also
activate members of the IRF family including IRF1 and IRF8,
that modulate a second wave of ISRE-dependent gene expression
(3, 4).
Rapid activation of nuclear factor-κB (NF-κB) and IRFs is
a result of TLR4 ligation (4–7). This leads to amplification
of the initial inflammatory response, exertion of antimicrobial
activities and initiation of acquired immunity. Several of the
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cytokines that are upregulated in the initial wave of immediate
early gene expression e.g., IFNβ and TNFα, induce a secondary
wave of STAT1 and STAT2 dependent gene expression and NF-
κB signaling, respectively (4, 8, 9). On the other hand, IL-6 leads
to the activation of STAT3.
IFNγ and TLR4 participate in signaling cross-talk through
combinatorial actions of distinct and overlapping transcription
factors on ISRE, GAS, ISRE/GAS, ISRE/NF-κB or GAS/NF-
κB binding sites. As such, inflammation-induced activation
of STAT1, STAT2, and STAT3, NF-κB and different IRFs
coordinates robust expression of multiple chemokines, adhesion
molecules, antiviral and antimicrobial proteins. Thus, signal
integration between IFNγ and LPS in vascular cells and
atheroma interacting immune cells modulates important aspects
of inflammation, with STATs being important mediators (7, 10).
JAK-STAT pathway inhibitory strategies are numerous and
one of the most promising is development of JAK inhibitors
(Jakinibs), which exhibit the pan-JAK effect, defined as cross-
binding to few JAKs e.g., FDA approved tofacitinib inhibits
both Jak1 and Jak2. The concept of STAT inhibition is
the more targeted approach, since STAT inhibitory strategies
focus on affecting STAT dimerization. By exploring the pTyr-
SH2 interaction area of STAT3, searches for STAT3-targeting
compounds are numerous and yielded many small molecules,
which can be called Statinibs (11, 12). Compared to Jakinibs these
compounds affect expression of pro-inflammatory cytokines
directly. Statinibs do not affect JAK-STAT signaling cascade
upstream of the STAT phosphorylation and do not abrogate
JAK action. Jakinibs might also influence, as a side effect,
other JAK targets like SOCS or other kinases (e.g., Src and
Abl). Of these STAT3-interacting compounds, STATTIC was
shown to inhibit activation, dimerization, nuclear translocation
of STAT3, and to increase apoptosis in STAT3-dependent
cancer cell lines [reviewed in (7, 13)]. Similarly, the small-
molecule STX-0119 was able to inhibit STAT3 dimerization and
suppress human lymphoma SCC3 cell growth, through apoptosis
and downregulation of known STAT3 targets. STX-0119 also
exhibited potent antitumor effects in vivo of SCC3 tumor-
bearing nude mice (14). Recently, we proposed a STAT cross-
binding mechanism for STATTIC and STX-0119, in which both
compounds target the SH2 domain of STAT1, STAT2, and STAT3
with similar affinity. We hypothesized that non-specific STAT-
inhibitors, by simultaneous blocking STAT1, STAT2, and STAT3
activity (pan-STAT action) and expression of pro-inflammatory
target genes, may be a promising avenue for the treatment of
CVDs.
To prove this, we developed a pipeline approach which
combines comparative in silico docking of multi-million CL
and CDL libraries to multiple STAT-SH2 models with in vitro
STAT inhibition validation, as a novel selection strategy for
STAT-targeting inhibitors. This approach allowed us to identify
a new type of multi-STAT inhibitor, C01L_F03 targeting the
SH2 domain of STAT1, 2, and 3 with equal affinity. Moreover,
we observed a similar STAT cross-binding mechanism for
STATTIC and STX-0119, leading to genome-wide inhibition
of pro-atherogenic gene expression directed by cooperative
involvement of STATs with IRFs and/or NF-κB. Consequently, a
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multi-STAT inhibitory strategy was applied to inhibit endothelial
cell (EC) migration, leukocyte adhesion to ECs and impairment
of mesenteric artery contractility under inflammatory conditions.
MATERIALS AND METHODS
Protein Model Preparation
Three-dimensional models of STAT1, STAT2, and STAT3 were
prepared based on the existing crystal structures for STATs
deposited in RCSB Protein Data Bank: 1YVL, unphosphorylated
STAT1 monomer; 1BF5, phosphorylated STAT1 dimer and
1BG1, phosphorylated STAT3 dimer [detailed description see
Czerwoniec et al. (15) and Szelag et al. (16)]. Based on Chimera
Dock Prep protocol AMBER ff99SB charges were applied to
human STAT1, 2, and 3 models (17). Highly conserved pTyr-
binding pocket (pY+0) and hydrophobic side-pocket (pY-X) in
SH2 domain were selected for docking and virtual screening
procedures. At the level of protein structures these SH2 domain
superficial cavities are essential for STAT activation and binding
of inhibitors (16, 18). To generate a “protomol,” “a pre-computed
molecular representation of an idealized ligand” we used a
ligand-based approach implemented in Surflex-Dock 2.6 (19). By
definition protomol acts as the molecular probe of the active site
to which ligands are matched (20). Ligand used to generate the
protomol for STATs included a four amino acids from STAT-SH2
specific pTyr-linker matching the selected sub-pockets [STAT1,
GpY701IK; STAT2, KpY690LK; STAT3, PpY705LK (15)].
Compound Library Selection and Small
Inhibitors Preparation
Two small compound libraries of Clean Leads (CL) and Clean
Drug-Like (CDL) were selected and downloaded from ZINC
Database, with ready-to-dock parameters of protonation state
and partial atomic charges (21). CL with molecular weight
between 250 and 350 g/mol are smaller than most drugs. CDL
chemical parameters fulfill criteria of the Lipinski‘s rule of five
(22, 23). CL are in general more soluble than their bigger CDL
cousins, and thus more likely to actually be assayed in vitro. In
2011 for the purpose of primary virtual screening (pre-screen) a
CL subset has been downloaded, containing at that time 712,426
compounds. During the next step, similarity screening in 2013,
CL subset in number of 4,591,276 and CDL subset in number of
13,195,609 compounds were selected.
Geometries of STAT3 inhibitors used for docking, STATTIC
(24) and STX-0119 (25) were obtained from ZINC Database
(code names ZINC00162014 and ZINC04107278 respectively).
The structures were provided in ready-to-dock, 3D formats with
molecules represented in biologically relevant forms (21).
Virtual Screening of Small Compound
Libraries
To select the top STAT1 inhibitors novel six-step virtual
screening procedure was employed. The applied strategy is
an antecedent to our more advanced protocol for big-scale
virtual screening, named CAVS [see Czerwoniec et al. (15)]. The
procedure used here is characterized by the following steps:
1. Pre-screen: For the CL library (712,426 compounds) docking
simulations to STAT1 were carried out using Surflex-Dock 2.6
(19). Pscreen algorithm with fast screening parameter settings
was employed (15, 20). For each compound we obtained
10 binding poses in the predefined area of the STAT1-SH2
domain. Additionally, each binding pose was supplied with
a Binding Score value (BS) representing the total predicted
binding affinity of the compound to the STAT1-SH2 domain.
Moreover, input of polar interactions to the BS (represented
by Polar Score) and the error rate of binding (represented by
Crash) were also calculated.
2. Primary filtering of inhibitors: For each compound the
best of ten binding poses was filtered out for further
analysis. Then, we compared the binding quality between
different compounds by using the STAT1-BS. Compounds
with the highest STAT1-BS values were selected, checked
for availability and 12 compounds (A01-L01) have been
purchased for initial experimental validation.
3. Similarity screen: Based on the experimental results the best
three compounds for STAT1 inhibition (C01, E01, and F01
from CL library) were used to perform a structural similarity
screening. The CL list containing now 4,591,276 structures
was screened with the criteria of at least 50% similarity to
C01, E01, and F01. 1129 CL compounds fulfilled these criteria.
Similarly, the CDL list with 13,195,609 structures was screened
for compounds with >50% similarity and a molecular weight
of≥300 g/mol, to include bigger structures which could target
a larger area of the SH2 domain. These criteria were fulfilled by
832 CDL compounds. Then for a total of 1,961 compounds,
similarity scores (SIM and RMSD) were calculated using
Surflex-Sim 2.6 (19) to assess the level of similarity to C01,
E01, and F01.
4. Re-screen: Repeated docking simulations of a total of 1,961
compounds from the similarity screen to STAT1, 2 and 3-
SH2 were carried employing the Surflex-Dock 2.6 pgeom
algorithm which is recommended for detailed studies of
relative alignments. More exhaustive parameter settings were
used for optimal pose prediction of the compounds (15, 20).
As a result, in the predefined area of STAT-SH2 domain we
obtained 20 binding poses of each compound.
5. Secondary filtering of inhibitors: For each compound the
best of 20 binding poses was filtered out for further analysis.
Then by using the “Comparative Binding Affinity Value” for
STAT1 [STAT1-CBAV, more details see Czerwoniec et al. (15)]
the binding between STAT1, 2 and 3 was compared for each
compound. Compounds with STAT1-CBAV≥0 were selected
for graphical validation.
6. Binding diversity of conformers: Finally, graphical validation
of the selected compounds was represented by the “ligand
binding pose variation” (LBPV). This parameter reflects the
docking accuracy. For detailed description of this procedure,
see Czerwoniec et al. (15). The LBPV range of [0.8–1.0]
represents low conformer diversity with very good binding
specificity of the compound to STAT-SH2, whereas the range
of [0.0–0.2] denotes high conformer diversity with poor
binding specificity. Finally, compounds with the highest
STAT1-CBAV and STAT1-LBPV values were selected, checked
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for availability and six compounds (C01L_A03 to C01L_F03)
have been purchased for further experimental validation.
Comparative Docking of STATTIC,
STX-0119, and C01L_F03
In order to compare STATTIC and STX-0119 with compounds
obtained from CL and CDL virtual screening, docking
simulations of STATTIC and STX-0119 to STAT1, 2 and 3
SH2 domain were performed with the pgeom algorithm (15, 20)
implemented in Surflex-Dock 2.6 (19). For each structure in the
predefined area of STAT-SH2 domain we obtained 20 binding
poses. Then, for each compound the best of twenty binding poses
was filtered out for further analysis. Finally, STAT1-CBAV was
determined to compare the binding between STAT1, STAT2, and
STAT3 for both compounds. Also, LBPV was used to validate the
docking accuracy.
Moreover, we performed more exact docking simulations
of STATTIC; two STATTIC analogs STB and STC; STX-0119;
C01 and C01L_F03 for STAT1, 2 and 3 [see Szelag et al. (16)].
Geometries of two STATTIC analogs, which displayed lesser
inhibition of STAT3 binding in vitro (13), were obtained from
ZINCDatabase (code names ZINC00162015 and ZINC00162011
respectively). The structures were provided in ready-to-dock, 3D
formats withmolecules represented in biologically relevant forms
(21). For all studied complexes of STAT1, 2 and 3 with STATTIC,
STB, STC, STX-0119, C01, and C01L_F03 HADDOCK ligand
docking protocol (26, 27) was used with addition of Surflex-
Dock protocol (pgeomx algorithm) (16) to estimate the 1G0
(free enthalpy change), which corresponds to the stability of
the complex in a protein-ligand interaction in the equilibrium.
More negative 1G0 (higher free enthalpy change) corresponds
to stronger interaction between ligand and the protein, which
reflects better complex stability.
In silico STAT-SH2 Mutagenesis
We have performed docking studies of STATTIC, STX-0119 and
C01L_F03 to wt and mutated STAT1, 2, 3 [with our STAT 3D
models described in (16)]. For this purpose, HADDOCK ligand
docking protocol (26, 27) was used with addition of Surflex-Dock
protocol (16) to estimate the 1G0 (free enthalpy change), which
corresponds to the stability of the complex in a protein-ligand
interaction in the equilibrium. We assumed that mutation of
selected a.a. to alanine would impair binding of studied inhibitors
to STAT1, 2, and 3-SH2 domain.
Cell Culture Experiments
Recombinant IFNα and IFNγ were purchased from Merck,
while LPS was provided by Sigma-Aldrich. C01 and C01L_A03-
C01L_F03 were purchased from Enamine; E01 from Asinex;
F01 from ChemDiv; STX-0119 from Merck and STATTIC
from Sigma-Aldrich. Rabbit polyclonal antibodies against
STAT1-pTyr701, tSTAT1, tSTAT2, tSTAT3 were obtained from
Santa Cruz, STAT2-pTyr689 and STAT3-pTyr705 form Merck.
Tubulin antibody was purchased from Merck and anti-
rabbit HRP-conjugated antibody from Sigma-Aldrich. Human
Microvascular Endothelial Cells (HMECs) (28) were provided
by the Center for Disease Control and Prevention (Atlanta,
GA) and cultured in MCDB-131 medium (IITD PAN, Wroclaw,
Poland) containing 10% of fetal bovine serum (FBS) (Gibco,
Thermo Fisher Scientific), 100 U/ml penicillin, 100µg/ml
streptomycin, 0.01µg/ml EGF, 0.05µM hydrocortisone and
2mM L-glutamine. At least 12 h before the experiment, full
medium was exchanged for serum starved-medium (containing
1% of FBS instead of 10%). After minimum 12 h-starvation
HMECs were pre-treated with various concentrations of
inhibitors: C01, E01, F01 (40 h) or C01L_F03 (48 h) or STATTIC
(8 h) or STX-0119 (24 h). Additionally, HMECs were treated with
200 U/ml of IFNα (1 h for protein isolation or 4 h for RNA
isolation), 10 ng/ml IFNγ (24 h or 8 h) and/or 1µg/ml LPS (8 h
or 4 h) or IL-6 (1 h) 100 ng/ml.
Western Blot Analysis
HMECs were washed with phosphate buffered saline (PBS)
and lysed using radio-immune precipitation assay (RIPA)
lysis buffer (50mM Tris-HCl, pH = 8.0, 150mM NaCl, 1%
Nonidet-40, 0.5% sodium deoxycholate, 0.1% SDS, 1% protein
inhibitor cocktail, 1% EDTA, 0.1% PMSF) and stored at −80◦C,
as described in Sikorski et al. (4). Lysates were quantified
using bicinchoninic acid (BCA) kit (Perce). Thirty micrograms
of protein were loaded on Blot 4–12% Bis-Tris Plus Gels,
electrophoresed and transferred to PVDF membranes (Santa
Cruz). All western blot analyses were performed with Snap ID
system (Merck). Membranes were blocked in 0.125% non-fat
dry milk or 1% BSA in TBS-Tween (TBS-T) and incubated
with primary antibodies (1:1000 pSTAT1, 1:500 tSTAT1, 1:500
pSTAT2, 1:500 tSTAT2, 1:3500 pSTAT3, 1:500 tSTAT3, 1:2000
tubulin) and then with secondary anti-rabbit HRP-conjugated
antibody (1:2,0000). Immunoreactive bands were visualized by
enhanced chemiluminescence (ECL) using Luminata Forte HRP
Substrate (Merck) and detected with G:Box System (Syngene).
After detection membranes were stripped with buffer containing
25mM glycine, 1% SDS, pH = 2.0 and re-probed. The software
Image Studio Lite from LI-COR Biosciences was used for western
blot quantification with α-tubulin as reference protein.
ChIP qPCR
ChIP experiments were performed as described by Daniel et al.
in (29) with minor modifications (29). Briefly, 15 mln cells
were seeded and pre-treated with 50µM of C01L_F03 48 h
and for 1 h with 200 U/ml of IFNα. Cross-linking with DSG
(Sigma) was performed for 45min and then with formaldehyde
(Sigma) for 10min. After fixation chromatin was sonicated with
a Diagenode Bioruptor Plus to generate fragments with length
of 200–1,000 bp. Chromatin was immunoprecipitated with
antibodies against pSTAT1, pSTAT2, pSTAT3, and NF-κB p65
(Cell Signaling Technology R©). Chromatin-antibody complexes
were precipitated with anti-IgA and anti-IgG paramagnetic beads
(Life Technologies). After four washing steps, complexes were
eluted and the cross-links reversed. DNA fragments were column
purified (Qiagen, MinElute). DNA was quantified with a Qubit
fluorometer (Invitrogen). After immunoprecipitation DNA was
quantified using quantitative PCR (qPCR) and normalized to
values obtained after amplification of unprecipitated (input)
DNA. Oligonucleotides sequences (Genomed) are in Table 1.
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TABLE 1 | List of primer sequences used in experimental procedures.
Gene
Name
Primer Sequence (5′ → 3′order)
Forward Reverse
ACTB ACAGAGCCTCGCCTTTGCCGAT ATCATCCATGGTGAGCTGGCGG
CXCL10 GCAGAGGAACCTCCAGTCTCAGCA AGAGAGAGGTACTCCTTGAATGCCAC
CXCL9 GTGGTGTTCTTTTCCTCTTGGG CTCACTACTGGGGTTCCTTGC
IFIT2 TCTTCCGTGTCTGTTCCATTC AGCTGAAAGTTGCCATACCG
IRF1 GTCCAGCCGAGATGCTAAGAGC TCTTCCGTGTCTGTTCCATTC
OAS2 CAATCAGCGAGGCCAGTAAT TCCAGGTTGGGAGAAGTCAA
CCL5 CCATATTCCTCGGACACCAC GGGTGACAAAGACGACTGCT
ICAM CAGCGGCTGACGTGTGCAGTAA TTGGGCGCCGGAAAGCTGTA
VCAM TCCAGGTGGAGCTCTACTCATTCCC TCCCATTCACGAGGCCACCACT
OAS2_ChIP CGCTGCAGTGGGTGGAGAGA GCCGGCAAGACAGTGAATGG
SOCS3_ChIP CCATTCGGGAGTTCCTGGAC TTGGCTTCTTGTGCTTGTGC
IRF1_ChIP
STAT1
CCAAACACTTAGCGGGATTC GAAATGACGGCACGCAG
IER3_ChIP CCACCACCAGACTTCATCCC GGAACTGCGGCAAAGTAGGA
IRF1_ChIP
NF-κB
CTCAACAGCCAAGTGTGACC GGCCAGCTTTACACCACAAG
RNA Isolation and Quantitative Reverse
Transcription-PCR (qRT-PCR) Analysis
Total RNA was isolated using GeneMATRIX Universal RNA
Purification Kit (EURx, Gdansk, Poland). 500 ng of total RNA
was subjected to reverse transcription and PCR amplification
was performed in Maxima SYBR Green/ROX qRT-PCR Master
Mix (Thermo Fisher Scientific) on the Eco qRT-PCR System
(Illumina). The amount of target gene in each sample was
normalized to β-actin (ACTB) endogenous control (1CT). Data
were transformed as described previously (30). Forward and
reverse primers used in experiments are depicted in Table 1.
Microarray Analysis
Firstly, before treatment HMECs were starved for 12 h in 1%
MCDB medium (IITD PAN, Wroclaw, Poland). Then cells
were incubated with C01L_F03 (50µM, 48 h) or STX-0119
(25µM, 24 h) or STATTIC (10µM, 8 h), IFNγ (10 ng/ml,
8 h) and LPS (1µg/ml, 4 h) before RNA isolation. RNA was
isolated from harvested cells with GeneMATRIX Universal RNA
Purification Kit (EURx, Gdansk, Poland) and then labeled with
Illumina R©TotalPrepTM RNA Amplification Kit (Thermo Fisher
Scientific). To obtain raw data Standard Illumina Expression
BeadChip HumanHT-12v4 hybridization protocol was used. To
avoid false results in case of all negative signals their value was
changed to one, then signals were log-transformed. For further
analysis, statistically significant average gene expression signals
from two independent biological repeats were taken for statistical
testing (GEO accession: GSE101508). Background subtraction
and quantile normalization were applied and genes significantly
(p-value ≤ 0.05) up-regulated at least 2-fold in any sample
were selected for further analysis. IFNγ+LPS responsive genes
that were commonly inhibited by C01L_F03, STATTIC or STX-
0119 were selected according to the following formula: Fold
Change (FC)IFNγ+ LPS/FCIFNγ+ LPS+ inhibitor value ≥4. Lists of
inhibited genes were compared by Venn diagram analysis in the
VennDiagram package in R (31). Identification of overlapping
genes was based on “Gene ID and name.”
Gene Ontology Enrichment Analysis
Two datasets from microarray analysis (IFNγ+LPS induced
genes; 731 in total; IFNγ+LPS responsive genes commonly
inhibited by C01L_F03, STATTIC, and STX-0119) were mapped
to gene ontology terms of biological process category using
GOrilla webserver (32, 33). A p-value of 10−3 was used as a
threshold and Illumina gene list from HumanHT-12v4 served as
a background model. Then all statistically significant enriched
GO categories were analyzed by REVIGO webserver (34) with
medium similarity (0.7) and SimRel semantic similarity measure
and mapped to Homo sapiens background to generate lists
without redundant GO terms. Finally, the top 12 enriched GO
terms with the highest fold enrichment for cells stimulated with
IFNγ+LPS were selected and compared to those treated with
tested compounds in presence of IFNγ+LPS.
Promoter Analysis
The initial list of 731 IFNγ+LPS induced genes was used for
promoter analysis. The list was uploaded into pSCAN webserver
(35) in search for ISRE, GAS and NF-κB binding sites. We
analyzed 950 bp upstream and 50 bp downstream of the
transcription start sites and obtained lists of overrepresented
transcription factor binding sites, including matrix similarity
score. Based on the results produced by pSCAN we chose
matrices for further analysis. For checking distribution of: ISRE
sequence we chose matrices: MA0652.1, MA0137.1, MA0.517.1;
for GAS sequence: MA0137.2 and MA0137.3 and for NF-κB
binding site: MA0105.1, MA0105.3. To prevent false positive
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results, we introduced threshold of matrix similarity score ≥
0.85 for potential GAS, ISRE and ≥ 0.90 for potential NF-κB
binding sites. To confirm “STAT specificity” of tested inhibitors,
produced gene lists were merged for each individual binding site
and compared with gene list of 159 genes inhibited commonly
by C01L_F03, STATTIC and STX-0119 [by Venn diagram
analysis by VennDiagram package in R (31)]. Identification of
overlapping genes was based on “Gene ID and name.” The next
step was to check if identified sequences may appear in one gene
simultaneously. For that purpose, lists of genes containing either
ISRE, GAS, NF-κB binding site were compared by Venn diagram
analysis according to previously used protocol.
In vitroWound Healing Assay
HMEC cells were split on 100mm dishes and plated to reach
high confluency. Cells then were starved in MCDB medium
(IITD PAN, Wroclaw, Poland) with 0.1% of FBS for 12 h. Next
step was to treat 2 dishes with 25µM of C01L_F03 and 2
dishes with 25µM of STX-0119. After 12 h of pre-incubation
with C01L_F03 or STX-0119 scratches in these dishes were
made. Another set of 2 dishes was treated with 10µM of
STATTIC 12 h before pictures were taken. At the same time
10 ng/ml of IFNγ and 1µg/ml of LPS were added to one dish
from each pair treated with C01L_F03, STX-0119 or STATTIC.
Additionally, scratches were also made in set of 2 dishes that
remained not treated with any inhibitor, one was used as an
untreated control and to the second only IFNγ and LPS were
added. Pictures were taken with Axio Observer.Z1 Microscope
(Zeiss) after 12 h since the moment when scratches were made.
The images acquired for each sample from two independent
repeats were further analyzed quantitatively by ImageJ (36). For
each image, 20 distances between one side of scratch and the
other were measured at certain intervals (µm). By comparing
the images from or inhibitor (with or without IFNγ+LPS
treatment) to control, the distances of each scratch closure were
obtained. Analysis of HMECs migration according to wound
healing in vitro, which was performed according to Liang et al.
(37).
Leukocyte-Endothelial Cell Interactions
Under Flow Conditions
Human umbilical vein endothelial cells (HUVECs) were isolated
by collagenase treatment (38, 39) and maintained in human
endothelial cell specific medium (EBM-2, Lonza, Verviers,
Belgium), supplemented with endothelial growth media (EGM-
2, Lonza) and 10% fetal bovine serum (FBS, Lonza). Cells up
to passage 1 were grown to confluence to preserve endothelial
features. Cells were incubated for 24 h in medium containing 1%
FBS prior to every experiment.
Mononuclear cells were obtained from buffy coats of healthy
donors by Ficoll Hypaque density gradient centrifugation (39,
40). The Glycotech flow chamber was assembled and placed
on an inverted microscope stage. Freshly isolated mononuclear
cells (1 × 106/ml) were then perfused across the endothelial
monolayers (HUVECs) unstimulated or stimulated with IFNγ
(10 ng/ml, PreproTech, London, UK) for 24 h and LPS (1µg/ml,
Sigma Aldrich, Madrid, Spain) for 4 h. In the experiments
cells were incubated with STATTIC 5µM for 4 h or 1µM
for 24 h, STX-0119 25µM or C01L_F03 50µM for 24 h. In
all experiments, leukocyte interactions were determined after
5min at 0.5 dyn/cm2. Cells interacting with the surface of the
endothelium were visualized and recorded (×20 objective, ×10
eyepiece) using phase-contrast microscopy (Axio Observer A1
Carl Zeiss microscope, Thornwood, NY) (41).
Ex vivo Contractility Studies
Four-month-old male C57Bl/6 mice were used for vascular
reactivity experiments. Animals were maintained under
standardized conditions with an artificial 12 h dark-light cycle,
with free access to food and water. All animal studies were
performed according to national guidelines and approved by the
institutional animal care committees of Spain.
Immediately following sacrifice, the mesentery was removed,
and placed in a Petri dish containing Krebs-Henseleit solution
(KHS) at 4◦C. The first branch mesenteric arteries (mean
internal diameter ranged between 200 and 250µm with non-
significant differences observed among the different groups of
mice) were dissected and mounted as ring preparations on a
small-vessel myograph (DMT, Aarhus, Denmark) to measure
isometric tension (42). Themicrovessels were exposed to 125mM
KCl to achieve a stable contraction, after which they were
washed three times with KHS and a further 30min. washout
period was allowed. At this point, the vascular segments
were maintained for 4 h prior to the exposure to increasing
concentrations of noradrenaline (NA; 10−10 to 10−6M) to
assess vascular contraction. In some experiments, the vascular
segments were exposed to STATTIC (1 nM), STX-0119 (10 nM)
or C01L_F03 (1µM), IFNγ (10 ng/ml for 3 h prior to NA
stimulation), and/or LPS (1µg/ml for 1.5 h prior to NA
stimulation) based on a previous report (10). Because of
incubation time limitations of the system (<8 h), we were able
to test STATTIC, C01L_F03 and STX-0119 only for 4 h prior to
NA stimulation.
Statistical Analysis
Results of qRT-PCR assay are presented as mean ± SEM
for three independent repeats. Results of wound healing
assay are presented as mean ± SEM for two independent
repeats. Data for both experiments were compared by two-
way ANOVA and unpaired two-tailed student T-test as
indicated. A probability value p < 0.0001 was considered
statistically significant. Results of mononuclear cell adhesion
to HUVEC assay are presented as mean ± SEM for five to
seven independent repeats. Data were compared by one-way
ANOVA and unpaired two-tailed student T-test. A probability
value p <0.05 was considered statistically significant. Results
of ex vivo contractility studies are presented as mean ±
SEM for six to eighteen independent repeats. Data were
compared by two-way ANOVA. A probability value p <0.05
was considered statistically significant. All statistical tests were
performed with GraphPad Prism version 7.0a for Mac OS X,
GraphPad Software, La Jolla California USA, www.graphpad.
com.
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RESULTS
Identification of C01, E01 and F01 as Novel
Low Potent STAT1-SH2 Inhibitory
Compounds
Potential STAT1-targeting inhibitors were selected from a CL
library, using the pre-screen algorithm (see Materials and
Methods), according to STAT1-BS. Compounds with the highest
STAT1-BS were checked for availability and 12 of them were
purchased (Table 2). These compounds, named A01 to L01,
displayed STAT1-BS from 8.51 for J01 (the highest) to 7.56
for A01 (the lowest). To test the inhibitory capacity of these
compounds toward STAT1 phosphorylation in vitro, we first
treated HMECs with LPS (1µg/ml for 4 h) in the presence
or absence of the individual compounds (200µM for 40 h).
Except for C01, E01, and F01 (Figures 1A,B), none of the other
compounds were able to inhibit STAT1 phosphorylation (not
shown). A representative experiment is shown in Figure 1A,
in which the phosphorylation and expression of STAT1, was
followed. Indeed, a dramatic reduction in phosphorylation, but
not total expression, of STAT1 could be observed in LPS-
stimulated cells pre-treated with C01, E01, or F01. Notably,
treatment with C01 resulted in partial inhibition, whereas
E01 and F01 completely inhibited STAT1 phosphorylation
(Figure 1B). Under similar conditions, 100µM of E01 and F01
only partially inhibited STAT1 phosphorylation, while in case of
50 or 25µM no inhibition could be observed (data not shown).
Next, we examined the in silico binding affinity of C01, E01,
and F01 to the SH2 domain of STAT1, including the pTyr-
binding pocket (pY + 0) and the hydrophobic pocket (pY-X).
C01 (ZINC08344970, structure shown in Figure S1) exhibited
binding affinity to pY+0 and pY-X of STAT1 (Figure 1C), in the
same way as F01 (ZINC13362660, structure shown in Figure S1).
On the other hand, E01 (ZINC09970661, structure shown in
Figure S1) only showed affinity for pY+0, but not to pY-X
and shifted toward the Ile-binding sub-site of the STAT1 pTyr-
linker (Figure 1C). STAT1-BS was the highest for E01 (8.36)
as compared to C01 (8.09) and F01 (7.78). Among these three
compounds C01 displayed a higher input of polar interactions
to the BS (6.9), than E01 (6.05) and F01 (6.62), but at the same
time the highest error rate of binding, represented by Crash
value of −1.66. E01 and F01 had significantly lower penalty
score for inappropriate binding to STAT1-SH2 domain, −1.27
and −1.04 respectively (Table 2). Together, this suggested that
C01, E01, and F01 inhibit STAT1 phosphorylation by targeting
the pY+0 and pY-X of its SH2 domain, however with low
potency.
C01L_F03 Exhibits Similarity to C01 and
Shows Potent STAT-SH2 Cross-Binding
To identify more potent variants of the above characterized
STAT1 inhibitors, a similarity screen on the CL list and
the CDL list of the ZINC database was performed for
compounds with a similarity of 50% to C01, E01, or F01.
Moreover, to target multiple sites of the SH2 domain only
CDL compounds with a molecular weight >300 g/mol
TABLE 2 | Docking characteristics (pscreen algorithm, STAT1-BS, Crash, and
Polar Score) of top 12 selected compounds from Clean Leads primary screen
bound to STAT1-SH2 domain.
ZINC ID STAT1-BS Crash Polar score
A01 ZINC04943450 7.56 −1.12 6.96
B01 ZINC05362485 7.71 −1.66 8.67
C01 ZINC08344970 8.09 −1.66 6.9
D01 ZINC09418732 7.63 −1.11 7.57
E01 ZINC09970661 8.36 −1.27 6.05
F01 ZINC13362660 7.78 −1.04 6.62
G01 ZINC13443544 7.81 −1.77 4.94
H01 ZINC15772297 7.79 −0.99 5.98
I01 ZINC20069236 7.76 −1.72 8.99
J01 ZINC20312047 8.51 −0.85 6.87
K01 ZINC07047084 7.58 −1.4 8.94
L01 ZINC08477975 7.66 −1.32 6.92
FIGURE 1 | C01, E01, and F01 inhibit LPS-induced STAT1 phosphorylation
(A). HMECs were treated with 200µM of tested compounds for 40 h and with
1µg/ml of LPS for 4 h. Protein extracts were collected and levels of pSTAT1,
tSTAT1 and α-tubulin were assessed by western blotting. Western
quantification (B). Bars represent mean quantification form 3 individual repeats
± SEM as error bars. Top-scored binding conformations of C01, E01, and F01
in the SH2 domain of STAT1 (C). C01, E01, and F01 compounds are shown in
stick representation and colored according to the atomic structure. pTyr-linker
is represented by green lines with pink pTyr residue. SH2 domain of STAT1 in
the surface representation is colored based on the distribution of the APBS
electrostatic surface potential (43). Positively charged regions are indicated in
blue and negatively charged regions in red. Docking simulations were
performed using Surflex-Dock 2.6 program (19, 20).
were included. Altogether 1961 compounds were analyzed
for C01, E01, and F01 similarity by Surflex-Sim 2.6 and
docked to the SH2 domains of STAT1, STAT2, and STAT3,
using the more accurate screening method with pgeom
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parameter settings in Surflex-Dock 2.6 (20). The compounds
were filtered by STAT1-CBAV(STAT2) >0 and STAT1-
CBAV(STAT3)>0 to compare binding affinities between STAT1,
2, and 3.
Two important observations could be made from the data
analysis. First, the most interesting compounds were all from
the CDL list with a molecular weight exceeding 300 g/mol.
Second, these compounds were mostly C01-like. Accordingly, six
compounds C01L_A03 to C01L_F03 (accompanying structures
are shown in Figure S2) were selected with STAT1-CBAV >0
(Table 3). Their STAT1-BS as well as their STAT1-CBAV values
were higher than those for E01 and F01, calculated using the
same pgeom parameter setting. In comparison to C01 all six
compounds displayed significant higher STAT1-BS, but in case
of STAT1-CBAV differences were not always observed. For
example, C01L_A03 contained the highest STAT1-BS (9.84), as
well as STAT1-CBAV (3.6 for STAT2 and 4.14 for STAT3). In
the docking model of STAT1 C01L_A03 bound to pY+0, pY-X
and partially the Ile sub-site (data not shown). C01L_C03, on
the other hand, bound to pY+0, while pY-X and the Ile sub-
site of STAT1 were only partially targeted (data not shown).
In case of C01-similarity, C01L_D03 and C01L_A03 displayed
highest C01-SIM values, 0.846 and 0.785, respectively. C01L_E03
and C01L_F03 had more similar structures in comparison to
the other compounds (see Figure S2). This correlated with
similar STAT1-BS and C01-SIM values for these two compounds
(Table 3). Moreover, their binding position in STAT1-SH2
was also comparable (data not shown). A more exhaustive
docking analysis was performed for C01L_F03 (ZINC05312694,
structure shown in Figure S2). The C01L_F03‘s STAT1-BS of
8.23 and a STAT1-CBAV(STAT3)< 1 (0.22), suggested STAT1
and STAT3-SH2 cross-binding (Table 3). This coincides with
the high conservation between these two STATs, sharing 50%
of global amino acid sequence homology, according to pairwise
sequence identity analysis (44). On the other hand, the higher
STAT1-CBAV(STAT2) for C01L_F03 (Table 3; 3.36) predicted
lower affinity for STAT2 than for STAT1 and STAT3. In
contrast, the C01 compound displayed similar STAT1-CBAV
for STAT2 and STAT3, 1.74 and 2.08 respectively, whereas
the STAT1-BS was lower by 1.5 than for C01L_F03 (Table 3).
The binding affinity of C01L_F03 to the individual STAT-SH2
domains, corresponded with the graphical analysis. According
to Table 3, from the top 20 optimized binding conformations
of C01L_F03 to STAT1-SH2, 19 (95%) favored pY+0 and pY-
X simultaneously. LBPV analyses for other STAT-SH2 revealed
that C01L_F03 also shares high affinity for pY+0 and pY-
X in case of STAT3 with LBPV0+X = 0.75 and much lower
for STAT2 with LBPV0+X = 0.2 (Table 4). These calculations
were supported by graphical presentation of the docking results
(Figure 2A) in which the top scored conformation of C01L_F03
for each individual STAT competed with pTyr binding to the
particular STAT-SH2 domain. In the docking model of STAT1-
SH2, C01L_F03 bound to pY+0 and pY-X similar to C01. The
same conformation could be observed in the STAT3-SH2. In
case of STAT2-SH2, C01L_F03 predominantly bound to pY+0,
but not to pY-X and shifted toward the Leu-binding sub-site
of the STAT2 pTyr-linker (Figure 2A). C01 in the STAT2-SH2
TABLE 3 | Docking characteristics (pgeom algorithm, STAT1-BS, STAT1-CBAV)
of C01L_A03-C01L_F03 bound to STAT1, STAT2, and STAT3-SH2 domain in
comparison to C01, E01 and F01 from primary screening, as well as C01-like
similarity analysis (C01-SIM, C01-RMSD).
Compound ZINC ID C01-
SIM
C01-
RMSD
STAT1-
BS
STAT1-
CBAV
(STAT2)
STAT1-
CBAV
(STAT3)
C01 ZINC08344970 1.000 0.00 6.73 1.74 2.08
E01 ZINC09970661 0.604 2.96 6.95 −1.65 −0.73
F01 ZINC13362660 0.567 2.40 6.38 −0.09 −0.19
C01L_A03 ZINC03470000 0.785 2.28 9.84 3.60 4.14
C01L_B03 ZINC05585448 0.771 2.82 8.31 2.19 1.19
C01L_C03 ZINC08712870 0.760 2.47 7.08 0.70 1.00
C01L_D03 ZINC08712921 0.846 2.84 7.30 1.50 1.78
C01L_E03 ZINC21128441 0.777 2.13 8.01 2.94 2.68
C01L_F03 ZINC05312694 0.767 2.75 8.23 3.36 0.22
domain, on the other hand, remained in a similar position as in
STAT1 and STAT3-SH2 domains. Together, the docking results
of C01 and C01L_F03 suggest higher potency of the latter toward
STAT1 inhibition, although with a certain degree of STAT-SH2
cross-binding.
C01L_F03 Inhibits IFNα and IL-6 Induced
Phosphorylation of STAT1, STAT2 and
STAT3 and Binding to Target Gene
Promoters and Their Expression
In addition to the docking experiments, the six compounds from
the similarity screen were tested for their potential to block
IFNα induced STAT phosphorylation. This led to the selection
of C01L_F03 as our most potent candidate (not shown).
To address STAT cross-binding specificity of C01L_F03 we
pre-treated HMECs for 48 or 24 h (data not shown) with various
concentrations of the compound (50, 25, and 10µM) in the
presence or absence of IFNα (200 U/ml) or IL-6 (100 ng/ml),
which were added 1 h before protein isolation. A representative
experiment is shown in Figure 2B and Figure S3 in which the
phosphorylation of STAT1, STAT2, and STAT3 was followed.
These results stand in line with our docking studies. IFNα
induced phosphorylation of all three STATs was almost fully
inhibited in the presence of 50µM and 25µM, and partially of
10µM and 5µM of C01L_F03 for 48 h (Figure 2C). A similar
inhibition pattern was observed for STAT3 phosphorylation
upon IL-6 treatment (Figure S3). Twenty-Four hour treatment
with C01L_F03 resulted only in partial inhibition with the
highest concentration (data not shown). Under the same
conditions levels of total STAT proteins were not influenced by
C01L_F03 treatment. After 48 h treatment with 50µMC01L_F03
exhibited cytotoxic effect causing death of approximately 30%
of cells (not shown). However, at a concentration of 25µM
barely any toxicity was visible. What is more 24 h treatment
with 50µM of C01L_F03 showed no toxicity (not shown).
The inhibitory effect of C01L_F03 was also studied at the
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TABLE 4 | Docking characteristics (pgeom algorithm, STAT1-BS, STAT1-CBAV, LBPV) of STATTIC, STX-0119, C01, E01, F01, and C01L_F03 bound to STAT1, STAT2,
and STAT3-SH2 domain.
Compound STAT1-BS STAT1-CBAV (STAT2) STAT1-CBAV (STAT3) STAT1-LBPV STAT2-LBPV STAT3-LBPV
STATTIC 4.70 −0.86 0.39 0.70 0.2X 0.90 0.05X 0.30 0.55X
STX-0119 4.36 −0.32 0.25 0.450+X 0.30+X 0.250+X
C01 6.73 1.74 2.08 0.50+X 0.450+X 0.350+X
E01 6.95 −1.65 −0.73 0.650+X 0.30+X 0.30+X
F01 6.38 −0.09 −0.19 0.20+X 0.20+X 0.30+X
C01L_F03 8.23 3.36 0.22 0.950+X 0.20+X 0.750+X
gene expression level. In agreement with the STAT cross-
binding characteristics from our docking results, C01L_F03
was able to completely inhibit IFNα-induced expression of
the multiple STAT- and IRF-target genes, CXCL10, IFIT2,
and OAS2 at 25µM and partially for 10µM pre-treated for
48 h (Figure 3A). The same was true for the STAT1 target
gene, IRF1 and the STAT3 target gene, SOCS3. To further
demonstrate that the effect of C01L_F03 on STAT target gene
expression was mediated by inhibiting binding of STATs to
target gene promoters, we performed immunoprecipitation
followed by qPCR on Chromatin extracted from untreated
or IFNα treated HMECs in the absence or presence of
50µMC01L_F03. Accordingly, using antibodies against pSTAT1,
pSTAT2, or pSTAT3, treatment with IFNα caused enhanced
binding of pSTAT1 and pSTAT2 to the promoter ISRE element
of OAS2 (Figure 3B), and respectively of pSTAT1 and pSTAT3
to IRF1 and SOCS3 containing GAS sites as compared to
untreated controls (Figure 3B). More important, the presence
of CO1L_F03 dramatically reduced this DNA-binding of the
different STATs (Figure 3B) and correlated with inhibition of
target gene expression (Figure 3A).
Stattic and STX-0119 Exhibit STAT
Cross-Binding in Analogy to C01L_F03
Recently, we proposed a similar STAT cross-binding mechanism
for STATTIC and STX-0119 (16), chemical structures of
STATTIC and STX-0119 are displayed in Figure S1. They
were previously discovered as direct STAT3 inhibitors by
high throughput screening (13) and virtual screening (25),
respectively. In analogy to C01L_F03, we decided to examine
this in more detail, by using a comparative docking strategy
combined with western and Real-time PCR analysis. Using the
pgeom algorithm, docking simulation of STATTIC and STX-
0119 in the STAT1, 2 and 3 SH2 domain resulted in 20 optimized
conformations for each compound. Moreover, corresponding BS
values were calculated for each individual STAT (not shown).
Table 3 shows the top STAT1-BS of STATTIC (4.70) and of
STX-0119 (4.36), as well as STAT1-CBAVs (STATTIC: −0.86 for
STAT2 and 0.39 for STAT3; STX-0119:−0.32 for STAT2 and 0.25
for STAT3). As becomes clear from the calculated STAT1-CBAVs,
both compounds exhibited nearly identical binding affinity to the
STAT1, 2 and 3 SH2 domain. In addition, STATTIC and STX-
0119 LBPV toward the STAT-SH2 pY+0 and pY-X cavities were
determined. Thus, the conformational tendencies of STATTIC
and STX-0119 to the STAT3-SH2 were calculated. According to
Table 4, from the top 20 optimized binding conformations of
STATTIC to STAT3-SH2, 6 (30%) favor pY+0 and 11 (55%)
fit to pY-X. LBPV analyses for other STAT-SH2 revealed that
STATTIC also shares partial affinity between pY+0 and pY-
X in case of STAT1 and STAT2 (Table 4) similar to STAT3.
From the top 20 optimized binding conformations of STX-
0119 to STAT3-SH2, only 5 (25%) of them favor both cavities
simultaneously, which is in the same range in case of STAT1
and STAT2 (Table 4). Graphical analysis of the docking results
(Figure 4A) was performed as a supplement to the numerical
values. For each individual STAT the top scored conformation
of STATTIC and STX-0119 competes with pTyr in binding to
the STAT-SH2 domain. Due to its small size and low molecular
weight STATTIC lacks STAT-SH2 binding specificity, which is
supported by our recent docking results. Because of targeting
both cavities (pY-0 and pY-X) with low BS difference (based on
CBAV) and weak affinity (based on LBPV) the same is true for
STX-0119.
Stattic and STX-0119 Inhibit IFNα-Induced
STAT1, STAT2 and STAT3 Phosphorylation
and Target Gene Expression
These findings were further validated in HMECs in vitro, by
testing the potential of STATTIC and STX-0119 at varying
concentrations to inhibit STAT phosphorylation induced by
IFNα. For STATTIC and STX-0119 (Figures 4B,C), we observed
inhibition of phosphorylation of STAT1, STAT2 and STAT3
in a concentration dependent manner (STATTIC: between 10
and 2.5µM for 8 h; STX-0119: between 25 and 6.25µM for
24 h). Corresponding with the effects shown at the STAT-
phosphorylation level both inhibitors also efficiently decreased
IFNα-induced gene expression of the multi-STAT and IRF-
targets CXCL10, OAS2 and IFIT2, the STAT1-only target IRF1
and STAT3-only target SOCS3 (Figures 5A,B). In comparison to
C01L_F03, STATTIC was the most potent one of the three tested
compounds. Moreover, all three compounds exhibited a certain
degree of cytotoxicity only at the highest used concentrations
(not shown).
Together our data provide a molecular basis for STAT-cross-
binding specificity of C01L_F03, STATTIC, and STX-0119 and
their potential to inhibit multi-STAT and IRF-target genes.
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FIGURE 2 | Top-scored binding conformations of C01 and C01L_F03 in the SH2 domain of STAT1, STAT2, and STAT3 (A). C01 and C01L_F03 compounds are
shown in stick representation and colored according to the atomic structure. pTyr-linker is represented by green lines with pink pTyr residue. SH2 domains of STAT1, 2
and 3 in the surface representation are colored based on the distribution of the APBS electrostatic surface potential (43). Positively charged regions are indicated in
blue and negatively charged regions in red. Docking simulations were performed using Surflex-Dock 2.6 program (19, 20). C01L_F03 inhibits IFNα induced
phosphorylation of STAT1, STAT2 and STAT3 (B). HMECs were treated with 50, 25, 10, and 5µM C01L_F03 for 48 h and with 200 U/ml of IFNα for 1 h. Protein
extracts were collected and levels of pSTAT1, pSTAT2, pSTAT3, tSTAT1, tSTAT2, tSTAT3 and α-tubulin were assessed by western blotting. Western quantification (C).
Bars represent mean quantification form 3 individual repeats ± SEM as error bars.
C01L_F03, STATTIC and STX-0119 Interact
With the SH2 Domain of STAT1, STAT2, and
STAT3
To provide evidence that STATTIC, STX-0119 and C01L_F03
concert their inhibitory actions through direct interaction with
the STAT-SH2 domain we performed docking simulations
in combination with STAT-SH2 in silico mutagenesis (see
Materials and Methods). As presented in Figure 6A, mutating
a.a. R602 in STAT1 (45), R601 in STAT2 (46) and R609
in STAT3 (47), resulted in a significant decrease in binding
stability (1G0) between the SH2 domains of STAT1, STAT2
and STAT3 and all three inhibitors. The same was true,
after mutating a second important a.a. K584 in STAT1 (48),
R583 in STAT2 and K591 in STAT3 (18), albeit to a lesser
extent (Figure 6A). A similar approach was used to compare
binding stability of STATTIC and published STATTIC analogs,
STB and STC, Figure S1 (13), and of C01L_F03 and C01
which differ in in silico binding affinity for STAT1, 2, and
3 (Table 4). As becomes clear from Figure 6B, STATTIC
analogs exhibit lower binding stability (1G0) for the SH2
domains of STAT1, 2 and 3 as compared to wt STATTIC.
Likewise, interaction between C01 and STAT1, 2 and 3,
corresponds with a lower binding stability (1G0) in relation to
C01L_F03.
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FIGURE 3 | C01L_F03 inhibits IFNα induced gene expression of CXCL10, IFIT2, OAS2, IRF1, and SOCS3 (A). HMECs were treated with 50, 25, 10 of C01L_F03 for
48 h and with 200 U/ml of IFNα for 4 h. RNA was isolated and subjected to qPCR analysis. Experiments were performed in 3 individual repeats, which were compared
by two-way ANOVA test and unpaired two-tailed student T-test. C01L_F03 inhibits IFNα stimulated binding of STAT1, STAT2 and STAT3 to the ISRE of OAS2, and
GAS of IRF1 and SOCS3, and LPS stimulated binding of p65 to the NF-κB binding site of IER3 and IRF1 (B). HMECs were treated with 50µM of C01L_F03 for 48 h.
Chromatin was isolated and subjected to IP with antibodies against pSTAT1, pSTAT2, pSTAT3 or NF-κB (p65), followed by qPCR analysis (primers are listed in
Table 1). Experiments were performed in 2 individual repeats, which were compared by two-way ANOVA test and unpaired two-tailed student T-test.
C01L_F03, STATTIC and STX-0119
Commonly Inhibit Cross-Talk Between
IFNγ and LPS in a “Multi-STAT” and
“STAT-Only” Manner
In a second set of experiments HMECs were treated with
IFNγ and LPS to further investigate the ability of C01L_F03,
STATTIC, and STX-0119 to inhibit pro-inflammatory and pro-
atherogenic signaling depending on multiple STATs, IRFs and
NF-κB. As shown in Figure 7, pre-treatment of HMECs with
C01L_F03, STATTIC or STX-0119 resulted in inhibition of
IFNγ+LPS induced gene expression of IFIT2, OAS2, CCL5,
CXCL10, CXCL9, ICAM1 and VCAM1, in a concentration
dependent manner. Pre-treating HMECs with IFNγ+LPS,
followed by STATTIC, or simultaneous treatment of IFNγ+LPS
with C01L_F03 or STX-0119 (representing a more therapeutic
mode), likewise resulted in potent inhibition of CXCL10,
IFIT2, and OAS2 expression (Figure S4). In general, the
different compounds displayed similar inhibition characteristics,
although sometimes minor variations could be observed. These
data suggested that C01L_F03, STATTIC and STX-0119 may
commonly block STAT cooperative promotor activation with IRF
and NF-κB mediated by IFNγ and LPS in human microvascular
endothelial cells. To provide further evidence for this, we decided
to study the genome-wide effect of C01L_F03, STATTIC and
STX-0119 on IFNγ+LPS-mediated vascular inflammation. For
this, we performed a microarray experiment on RNA isolated
from HMECs treated with IFNγ+LPS in the presence or absence
of: 50µM of C01L_F03, 25µM of STX-0119 or 10µM of
STATTIC (GEO accession: GSE101508). IFNγ+LPS increased
the expression of 731 genes at least two-fold or higher as
compared to untreated cells, of which the top-25 are shown in
Table 5.
These included many known IFNγ and LPS target genes
associated with: chemotaxis/migration (CXCL9, CXCL10,
CCL7, CCL8, CCL3L3, MMP3, MMP12), adhesion (VCAM1,
CD74), immune response to viral infection (UBD, GBP4,
GBP5, OAS2, MX2, INDO, OASL, IFI44L, MX2). GO
analysis of the complete list of IFNγ+LPS responsive genes
revealed enrichment of biological functions mainly involved in:
cytokine-mediated signaling pathway (GO:0019221); defense
response and immune system process (GO:0006952 and
GO:0002376); regulation of cytokine production (GO:0001817),
inflammatory response (GO:0006954), regulation of cell
adhesion (GO:0030155) or cell migration (GO:0030334), (see
Table 5, Figure 8A).
Next, we aimed at identifying the IFNγ+LPS target genes
that were commonly inhibited by C01L_F03, STX-0119 and
STATTIC. For this, genes were considered of which the
expression was more than 4 times inhibited by all three inhibitors
as compared to IFNγ+LPS alone (see Materials and Methods).
As such, out of the 731 up-regulated genes C01L_F03 inhibited
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FIGURE 4 | Top-scored binding conformations of STATTIC and STX-0119 in the SH2 domain of STAT1, STAT2, and STAT3 (A). STATTIC and STX-0119 compounds
are in stick representation and colored according to the atomic structure. pTyr-linker is represented by green lines with pink pTyr residue. SH2 domains of STAT1, 2
and 3 in the surface representation are colored based on the distribution of the APBS electrostatic surface potential (43). Positively charged regions are indicated in
blue and negatively charged regions in red. Docking simulations were performed using Surflex-Dock 2.6 program (19, 20). STATTIC and STX-0119 inhibit IFNα
induced phosphorylation of STAT1, STAT2 and STAT3 (B). HMECs were treated with 10, 5, 2.5µM of STATTIC for 8 h or with 25, 12.5, 6.25µM of STX-0119 for 24 h
and with 200 U/ml of IFNα for 1 h. Protein extracts were collected and levels of pSTAT1, pSTAT2, pSTAT3, tSTAT1, tSTAT2, tSTAT3 and α-tubulin were assessed by
western blotting. Western quantification (C). Bars represent mean quantification form 3 individual repeats ± SEM as error bars.
expression of 259, STATTIC of 244 genes and STX-0119 of
292 genes (Figure 8B). What is more, expression of 159 genes
was commonly inhibited by C01L_F03, STATTIC and STX-
0119 (according to the requirements specified in Materials
& Methods), of which the inhibition pattern of the top-25
is displayed in Figure 8C. Among those we could recognize
the ones which were already validated by Real-time PCR
(Figures 3A, 5A,B, 7) e.g., CXCL10, IFIT2, OAS2, or VCAM1,
as well as many known STAT target genes (i.e., SOCS1, IRF1,
IRF8, APOL1, BID as STAT1 targets; IFIT1, IFIT2, IFIT3, OAS1,
OAS2, MX1, MX2, ISG15 as STAT1-STAT2 targets; SOCS3,
CCND1, MMP3, FAS PIM1, VEGF, S1PR1 as STAT3 targets).
GO analysis of the 159 commonly inhibited genes furthermore
revealed enrichment of biological functions connected to pro-
inflammatory and pro-atherogenic responses (Figure 8C). The
complete list of up and down-regulated genes in response to
IFNγ+LPS in the presence or absence of C01L_F03, STATTIC
and STX-0119 is shown in Table S1.
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FIGURE 5 | STATTIC and STX-0119 inhibits IFNα induced gene expression of CXCL10, IFIT2, OAS2, IRF1, and SOCS3. HMECs were treated with (A) 10, 5, 2.5µM
of STATTIC for 8 h or (B) with 25, 12.5, 6.25µM of STX-0119 for 24 h and with 200 U/ml of IFNα for 4 h. RNA was isolated and subjected to qPCR analysis.
Experiments were performed in 3 individual repeats, which were compared by two-way ANOVA test and unpaired two-tailed student T-test.
FIGURE 6 | Comparison of wt and mutated STAT-SH2/ligand complex stability (A). STAT1, 2 or 3, wild type and with single point mutation to Ala, complexes with
STATTIC, STX-0119 or C01L_F03 have been subjected to the in silico studies of binding stability in the equilibrium. 1G0 (free enthalpy change), which is a measure of
the strength of the complex formation was estimated [based on HADDOCK ligand docking protocol (26, 27) with addition of Surflex-Dock protocol (16)]. More
negative 1G0 (higher free enthalpy change) corresponds to stronger interaction between ligand and the protein, which reflects better complex stability. Comparison of
STAT-SH2/ligand complex stability (B). Complexes of STAT1, 2 and 3, with STATTIC and its analogs STB and STC, as well as C01 and C01L_F03 have been
subjected to the in silico studies of binding stability in the equilibrium as in (A).
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FIGURE 7 | C01L_F03, STATTIC and STX-0119 inhibit IFNγ+LPS induced gene expression of IFIT2, OAS2, CCL5, CXCL10, CXCL9, ICAM1, and VCAM1. HMECs
were treated with (A) 50, 25, 10µM of C01L_F03 for 48 h or (B) 10, 5, 2.5µM of STATTIC for 8 h or (C) with 25, 12.5, 6.25µM of STX-0119 for 24 h and for 8 h with
IFNγ + 4 h with LPS. RNA was isolated and subjected to qPCR analysis. Experiments were performed in 3 individual repeats, which were compared by two-way
ANOVA test and unpaired two-tailed student T-test.
To address the “multi-STAT” and “STAT-only” characteristics
of these three inhibitors, we subsequently performed promoter
analysis on the 159 commonly inhibited genes, for the presence
of ISRE, STAT or NF-κB binding sites. Figure 8D shows the
predicted representation of individual or combined ISRE, STAT
or NF-κB binding sites, in their proximal promoters (−950 to
+100). Themajority of these genes contained single ISRE (14.9%)
or GAS (17.5%) sites, or combinations of ISRE+GAS (19.3%),
ISRE+NF-κB (5.3%), GAS+NF-κB (18.4%) or ISRE+GAS+NF-
κB (22.8%). In general, under these conditions ISRE motifs
correspond to potential binding of multiple STATs (STAT1 and
STAT2) and IRFs (IRF1, IRF8, and IRF9), and GAS motifs to
that of multiple STATs (STAT1 and STAT3). Surprisingly, 2 genes
(1.8%), IL7R, USP18 were assigned to the group with only an
NF-κB site in their proximal promoter. However, both genes
contained either a GAS (IL7R) or ISRE (USP18) sequence just
outside the 950 bp selected promoter area (not shown). To
further proof that DNA binding of NF-κB (p65) was not affected
under these conditions we performed ChIP qPCR on genes
containing either both STAT1 and NF-κB binding sites (IRF1)
or only an NF-κB binding element (IER3) (Figure 3B). Indeed,
C01L_F03 did not effect the LPS-induced DNA binding of p65
to the promoter of these two genes, which correlated with the
partial (IRF1) or lack of inhibition (IER3) of their expression
as observed in our microarray experiment (Table S1). These
results strongly suggest that C01L_F03, STATTIC and STX-0119
are “multi-STAT” and “STAT-only” inhibitors that commonly
inhibit pro-inflammatory and pro-atherogenic gene expression
directed by cooperative involvement of STATs with IRFs and/or
NF-κB.
C01L_F03, STATTIC and STX-0119 Inhibit
IFNγ+LPS Induced VSMC Migration
In addition, we aimed at providing evidence that a multi-
STAT inhibitory strategy could be used to inhibit IFNγ+LPS
induced vascular inflammation in different models. First, we
performed a wound healing assay to examine the effect of
all three compounds on IFNγ+LPS induced ECs migration
(Figure 9A). Cells stimulated with IFNγ+LPS showed
increased capacity of migration, resulting in almost 80%
wound coverage after 12-h of treatment (Figure 9B). In contrast,
HMECs treated additionally with C01L_F03, STATTIC or
STX-0119 demonstrated drastic reduction of movement.
All three inhibitors caused decrease of IFNγ+LPS induced
wound healing to less than 15% (Figure 9B), whereas in
the absence of IFNγ+LPS they were not capable of closing
more than 10% of the artificial wound (Figure 9B). In
agreement with the effect on IFNγ+LPS-induced gene
expression (Figure 8), based on concentration and time
of treatment, STATTIC was the most potent of the three
compounds.
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TABLE 5 | Representative top-25 genes induced by IFNγ+LPS, displaying
significant inhibition by all three compounds.
Gene id Fold change relative to control
IFNγ+LPS C01L_F03 STATTIC STX-0119
CXCL10 9298.61 615.79 15.14 223.90
CCL8 2118.86 6.83 6.31 0.79
UBD 1860.83 129.28 2.09 62.19
CXCL9 1565.00 2.26 1.00 6.31
GBP4 793.16 38.79 16.30 8.61
GBP5 435.89 20.26 5.26 11.63
OAS2 329.65 2.61 6.29 1.48
VCAM1 326.83 33.01 1.36 8.12
CCL7 289.01 1.00 3.41 1.00
INDO 209.33 1.00 1.80 1.00
MMP3 192.62 2.22 28.96 2.89
IDO1 178.80 1.62 6.03 1.42
CCL3L3 165.18 4.69 1.52 20.25
OASL 160.22 3.99 1.21 14.16
LYPD5 127.07 6.75 6.90 7.66
LTB 125.33 1.00 0.75 0.95
MMP12 111.79 0.70 0.70 0.70
IFI44L 100.04 1.14 1.14 1.21
LOC730249 91.23 0.60 0.96 0.78
CD74 88.67 1.18 0.76 0.84
LOC100129681 76.64 1.31 2.35 0.18
MX2 68.99 0.40 0.74 1.23
DLL1 68.78 3.39 10.80 8.11
C1S 64.57 4.22 5.98 2.39
TNFSF10 64.45 0.67 1.22 0.21
Gene expression levels were presented as fold change relative to control.
C01L_F03, STATTIC and STX-0119 Inhibit
IFNγ and LPS Induced Mononuclear
Leukocyte Adhesion to HUVECs
Our previous studies reported increased adhesion of monocytes
to ECs in vitro under static conditions in response to
IFNγ and LPS in a STAT1-dependent manner (4). We
next evaluated the effect of IFNγ for 24 h followed by
LPS for another 4 h challenge on mononuclear-endothelial
cell interactions in vitro using the dynamic flow chamber
assay. Thus, freshly-isolated human mononuclear cells were
perfused across HUVECs monolayers stimulated or not with the
IFNγ+LPS combination. Significant increases in mononuclear
cell adhesion were detected in stimulated cells compared
to untreated cells (Figure 10). Treatment with C01L_F03
(50µM; Figure 10A), STATTIC (5µM; Figure 10B) or STX-
0119 (25µM; Figure 10C) for 4 h or 24 h resulted in significant
inhibition of mononuclear cell adhesion to ECs induced by
the IFNγ+LPS combination. In the presence of a lower
concentration of STATTIC, 1µM (24 h), a similar drastic
reduction in the number of adhered mononuclear cells induced
by the IFNγ+LPS combination was observed >70% inhibition,
Figure 10B).
C01L_F03, STATTIC and STX-0119 Protect
Against IFNγ and LPS Induced Impairment
of Mesenteric Artery Contractility
Recently we also observed that among the genes that were highly
amplified upon treatment with IFNγ and LPS in primary mouse
VSMCs, appeared inducible nitric oxide synthase (iNOS, Nos2).
Dysregulation of Nos2 expression and its activity affect vessel
function. Thus, we evaluated the physiological ramifications of
these experimental conditions using a wire myograph/organ
chamber setting. Here we examined the possible protective effect
of a multi-STAT inhibitory strategy under similar conditions. As
expected, stimulation of the mesenteric arteries isolated from
WT animals with IFNγ+LPS resulted in drastic impairment
of contractility after subjection to NA treatment as compared
to matched control arteries (Figure 11A). Nevertheless, pre-
incubation with C01L_F03 (1µM), STATTIC (1 nM) or STX-
0119 (10 nM) prevented the impaired response to NA elicited
by IFNγ+LPS (Figures 11B–D respectively). Notably, STATTIC
and STX-0119 could only be used in the nM range, without
causing IFNγ+LPS-independent impairment of vessel function
and integrity (not shown).
DISCUSSION
Abnormal activation of STAT pathways is present in many
human diseases, including CVDs. This fact marks these proteins
as highly interesting therapeutic targets (49, 50). By exploring
the pTyr-SH2 interaction area of STAT3, searches for STAT3-
targeting compounds yielded many small molecules including
STATTIC and STX-0119. Only a few inhibitors for other STATs
are described. In our pursuit for novel STAT inhibitors, we used
a comparative in silico docking strategy on CL library from ZINC
in combination with 3D structure models for human (h)STAT1,
2 and 3. We selected three novel STAT1 inhibitors C01, E01,
and F01 that inhibit STAT1 phosphorylation by targeting the
pY+0 and pY-X of its SH2 domain, however with low potency
(Figure 1). To find more potent variants of these compounds, a
similarity screen on the CL and the CDL libraries of the ZINC
database was performed for compounds with a similarity of ≥
50% to C01, E01 or F01 (Tables 3, 4). Consequently, we identified
the novel multi-STAT inhibitor C01L_F03, which targets the SH2
domain of STAT1, STAT2, and STAT3 with the same affinity
(Figure 2). In addition, it was shown to simultaneously block
phosphorylation and DNA-binding of these three STATs and
expression of a selection of target genes in ECs in response
to IFNα (Figures 2, 3). These included the multiple STAT
(STAT1/STAT2)-target genes, CXCL10, IFIT2 and OAS2, as well
as the STAT1 target gene, IRF1 and the STAT3 target gene,
SOCS3. It also predicts anti-inflammatory potential of C01L_F03
by simultaneous inhibiting STAT1, STAT2, and STAT3 activity.
According to a similar docking strategy, recently we obtained
further insight into the STAT-SH2 cross-binding specificity of
a pre-selection of known STAT3 inhibitors, including STATTIC
and STX-0119 (16) (Table 4). All the studied compounds targeted
the highly conserved pTyr-SH2 binding pocket of all STATs. We
concluded, based on the binding affinity scores (BS) and graphic
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FIGURE 8 | Comparison of top GO terms (A). Terms were selected based on Fold Enrichment values, between genes induced by treatment with IFNγ+LPS and
group of IFNγ+LPS induced and inhibited simultaneously by three compounds. Venn diagram distribution of IFNγ+LPS induced and inhibited (C01L_F03, STATTIC,
STX-0119) genes (B). Data were obtained from HMECs treated with 50µM of C01L_F03, 10µM of STATTIC and 25µM of STX-0119 and IFNγ+LPS. Three lists of
inhibited genes were uploaded and analyzed by VennDiagram package in R (31). The diagram shows how many genes are induced by IFNγ+LPS and simultaneously
inhibited by two or three inhibitors or only by one compound. Representative genes induced by IFNγ+LPS, displaying significant inhibition by all three compounds (C).
Expression levels of IFNγ+LPS-induced genes (displayed as •, left Y-axis) were presented as fold change (FC) relative to control. Expression of C01L_F03 or STATTIC
or STX-0119 inhibited genes (displayed as colored bars, right Y-axis) was presented as percent of IFNγ+LPS-induced FC. Venn diagram distribution of ISRE, GAS,
NF-κB binding sites among genes inhibited simultaneously by three compounds (D). Three lists of inhibited genes were uploaded and analyzed by VennDiagram
package in R (31).
FIGURE 9 | Wound healing assay performed on HMECs treated with C01L_F03, STATTIC and STX-0119 with or without IFNγ+LPS presence (A). Dashed lines
determine scratch borders at the beginning of the experiment. Statistical evaluation of wound healing assay (B). Graph shows percentage of healed wound in
comparison to 0 h control. Experiment was performed in 2 individual repeats (40 distance measurements in total), which were compared by two-way ANOVA test.
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FIGURE 10 | C01L_F03, STATTIC, STX-0119 and inhibit IFNγ+LPS-induced HUVECs mononuclear cell adhesion under physiological flow. HUVECs were stimulated
with IFNγ (10 ng/ml) for 24 h and LPS (1µg/ml) for 4 h. In the experiments, cells were pretreated with (A) C01L_F03 50µM for 4 h or C01L_F03 50µM for 24 h; (B)
STATTIC 5µM for 4 h or STATTIC 1µM for 24 h; (C) STX-0119 25µM for 4 h or STX-0119 25µM for 24 h. Freshly isolated human mononuclear cells (106 cells/ml)
were perfused across the endothelial monolayers for 5min. at 0.5 dyn/cm2 and leukocyte adhesion quantified. Experiments were performed in 5–7 individual repeats,
which were compared by one-way ANOVA test and unpaired two-tailed student T-test with *p < 0.05; **p < 0.01 and ***p < 0.001.
FIGURE 11 | Ameliorated response to noradrenaline in mesenteric arteries stimulated with IFNγ and LPS (A). Isolated mesenteric arteries from WT mice were
incubated with IFNγ (10 ng/ml for 3 h prior to NA stimulation), and/or LPS (1µg/ml for 1.5 h prior to NA stimulation). Next, response to noradrenaline was tested on the
small-vessel myograph. C01L_F03, STATTIC and STX-0119 prevent the impaired response to NA elicited by IFNγ+LPS treatment. Isolated mesenteric arteries from
WT mice were pre-incubated with (B) C01L_F03 (1µM for 4 h) or (C) STATTIC (1 nM for 4 h) or (D) STX-0119 (10 nM for 4 h) prior to NA stimulation and/or IFNγ
(10 ng/ml for 3 h prior to NA stimulation) and LPS (1µg/ml for 1.5 h prior to NA stimulation). Next, response to noradrenaline was tested on the small-vessel
myograph. Response to noradrenaline in WT mice presented as a percentage of the maximal contraction to KCl. Two-way ANOVA test was used with *p < 0.05 vs.
Control and +p < 0.05 vs. IFNγ+LPS.
representation in the SH2 domain of hSTAT1, hSTAT2 and
hSTAT3, that none of these compounds are STAT3-specific. Here,
we followed up on the proposed STAT cross-binding specificity
of STATTIC and STX-0119. As compared to C01L_F03, a similar
in silico and in vitro multi-STAT inhibiting capacity was shown
for STATTIC and STX-0119 (Figures 4, 5). STATTIC was the
most potent of the three compounds, reflected by the time of
treatment and concentration used. This could agree with the
fact that STATTIC is the smallest compound of the three, and
equally targeted the pTyr-binding or hydrophobic SH2 cavity.
In addition, the covalent binding of STATTIC has shown to
contribute to its potent inhibitory activity toward STAT3 (51).
In contrast, the larger two compounds C01L_F03 and STX-0119
covered both pTyr-binding and hydrophobic SH2 cavities for
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binding, at the same time. Not surprisingly, the non-specific
in silico binding of STATTIC and STX-0119 toward all STATs
(STAT1-STAT6) (16), could also be observed for C01L_F03
(data not shown). Together our data provide a molecular basis
for STAT-cross-binding specificity of C01L_F03, STATTIC, and
STX-0119 and their potential to inhibit multi-STAT-activity and
target gene expression.
In general STAT direct inhibitors are a very heterogenous
group considering their chemical attributes e.g., peptides,
peptidomimetics, natural and synthetic small compounds. In
our work we concentrated on small compounds targeting
STAT-STAT dimerization plane between pTyr linker and SH2
domain, with pTyr-binding cavity as a main interaction site.
Since interaction between negatively charged pTyr residue and
positively charged Arg and Lys in the cavity is very relevant for
STAT-STAT dimerization, the main driving force of the binding
are polar and electrostatic interactions. Thus, we postulate that
the general common chemical attribute of STAT inhibitors might
be negatively charged side group analogous to pTyr phosphate
(which is common for the tested compounds). Our results
are in agreement with other studies on the binding mode of
STAT inhibitors, e.g., Arpin et al. (52) who reported a novel
STAT3 small molecule inhibitor PG-S3-001 as a pancreatic cancer
therapeutic. They performed detailed in silico characteristics of its
binding to the STAT3-SH2 domain. Similar to their results, in our
docking studies STATTIC, STX-0119, and C01L_F03 targeted
the pTyr-binding cavity and exhibited polar and electrostatic
interactions between negatively charged side groups and the
same amino acids as reported by Arpin et al. (52) For example,
PG-S3-001 binds with Arg609, Lys591 and Ser611 by carboxyl
group, whereas STATTIC interacts with the same amino acids in
STAT3 by the nitro group and the corresponding amino acids in
STAT1 and STAT2. Moreover, STX-0119 and C01L_F03 possess
a relatively flexible glycine core similarly to PG-S3-001.
The comparative docking simulations and in vitro inhibition
studies related to STAT-cross-binding specificity correspond to
other studies. For example, Bill et al. provided evidence for cross-
binding of curcumin to STAT3 and STAT1 (53). Other natural
products like cryptotanshinone (54) and resveratrol analogs
(RSVA314 and RSVA405) (55) exhibited similar characteristics.
Sanseverino et al. found that STATTIC inhibits not only STAT3
activation but also that of STAT1 and to a lesser extent of
STAT2, in response to cell activation by IL-6 or IFNβ based on
studies using human monocyte-derived dendritic cells (56). This
correlates with our finding, that STATTIC is not STAT3 specific.
Inhibition of STAT1 phosphorylation by STATTIC has also been
described in human ovarian cancer cells (57) and melanoma cells
(58). Therefore, evidence accumulates that many of the known
STAT3 inhibitors do not seem STAT3 specific.
Docking simulations of C01L_F03, STATTIC, and STX-0119
in combination with in silico STAT-SH2 mutagenesis provided
further evidence to suggest that these compounds directly
interact with hSTAT1, hSTAT2, and hSTAT3 (Figure 6). In this
respect, docking simulations highly correlated with in vitro
mutagenesis studies of a.a. R602 in STAT1, R601 in STAT2
and R609 in STAT3, which were experimentally proven to be
crucial for STAT phosphorylation and reciprocal binding of the
pTyr-linker to the STAT-SH2 domain [STAT1-R602 (45); STAT2-
R601 (46); STAT3-R609 (47)]. The same was true, for the second
mutation a.a. K584 in STAT1 (48), R583 in STAT2 and K591
in STAT3 (18). In case of STATTIC and its selective binding to
STAT3, the lower STAT3 binding affinity of published STATTIC
analogs, STB and STC (13)] coincided with decreased binding
stability toward STAT-SH2 models (Figure 6). Combined with
the observed in vitro effects of C01L_F03 on STAT DNA-binding
(Figure 3) this strongly suggests that all three compounds
act as direct STAT-inhibitors. This is also in line with the
finding that the activation state of the tyrosine kinases JAK1,
JAK2, and c-Src, which are considered to be responsible for
phosphorylation of STAT3 Tyr705, was not significantly inhibited
by the presence of 10 or 20mM STATTIC in breast cancer cells
(13).
Of all STATs especially STAT1, STAT2, and STAT3 have been
recognized as prominent modulators of inflammation, especially
in immune and vascular cells during atherosclerosis (7, 59).
However, STAT-inhibitory strategies targeting CVDs, still await
entering the clinic. Based on the newly identified STAT cross-
binding mechanism for C01L_F03, STATTIC, and STX-0119,
we subsequently pursued a multi-STAT inhibitory approach as
a novel strategy in the treatment of vascular inflammation and
CVDs. Along these lines, we first tested the effect of C01L_F03,
STATTIC, and STX-0119 on signal integration between IFNγ and
LPS, which in vascular cells and atheroma interacting immune
cells modulates important aspects of vascular inflammation
(10) (Table 6). Indeed, pre-treatment of ECs with C01L_F03,
STATTIC, or STX-0119 resulted in a similar inhibition pattern
of IFNγ+LPS induced expression of the genes IFIT2, OAS2,
CCL5, CXCL10, CXCL9, ICAM1, and VCAM1, with STATTIC
being the most potent one (Figure 7). Likewise, STATTIC
potently inhibited expression of the pro-inflammatory and pro-
atherogenic genes CXCL9, CXCL10, CCL5, Nos2, IFIT1, and
OAS2 in VSMCs treated with IFNγ and LPS (not shown).
This suggested that C01L_F03, STATTIC, and STX-0119 may
commonly block STAT cooperative promotor activation with IRF
and NF-κB mediated by IFNγ and LPS in ECs and VSMCs.
To provide further evidence for this, we decided to study the
genome-wide effect of C01L_F03, STATTIC and STX-0119 on
IFNγ+LPS-mediated vascular inflammation (Figure 8). Thus,
IFNγ+LPS increased the expression of 731 genes, of which 159
were commonly inhibited by C01L_F03, STATTIC, and STX-
0119. These 159 genes generally represented the ones with the
highest IFNγ+LPS inducible levels and their biological functions
reflected strong inhibitory potential of C01L_F03, STATTIC,
and STX-0119 toward pro-inflammatory and proatherogenic
responses. Among those genes many known STAT target genes
(i.e., SOCS1, IRF1, IRF8, APOL1, BID as STAT1 targets; IFIT1,
IFIT2, IFIT3, OAS1, OAS2, MX1, MX2, ISG15 as STAT1-STAT2
targets; SOCS3, CCND1, MMP3, FAS PIM1, VEGF, S1PR1 as
STAT3 targets) could be recognized. More important, promoter
analysis of the 159 commonly inhibited genes, for the presence
of ISRE, STAT or NF-κB binding sites provided additional
evidence that C01L_F03, STATTIC, and STX-0119 are “multi-
STAT” as well as “STAT-only” inhibitors that commonly inhibit
pro-inflammatory and pro-atherogenic gene expression directed
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TABLE 6 | Comparison of top-12 GO terms, selected based on Fold enrichment values, between genes induced by treatment with IFNγ+LPS and group of IFNγ+LPS
induced and inhibited simultaneously by C01L_F03, STATTIC, and STX-0119.
GO Term Biological process Induced by IFNγ and LPS Inhibited by C01L_F03, STATTIC and STX-0119
Fold enrichment Uniqueness Dispensability Fold enrichment Uniqueness Dispensability
GO:0043207 Response to external biotic stimulus 55.28 0.84 0.00 28.14 0.82 0.11
GO:0009607 Response to biotic stimulus 54.84 0.92 0.12 27.38 0.92 0.12
GO:0006952 Defense response 52.46 0.88 0.43 29.61 0.88 0.43
GO:0019221 Cytokine-mediated signaling pathway 52.09 0.74 0.11 29.62 0.76 0.00
GO:0002376 Immune system process 49.72 1.00 0.00 28.66 0.99 0.00
GO:0001817 Regulation of cytokine production 37.65 0.83 0.00 10.67 0.81 0.05
GO:0007166 Cell surface receptor signaling pathway 28.05 0.79 0.28 13.89 0.81 0.28
GO:0006954 Inflammatory response 27.36 0.86 0.68 8.28 0.87 0.68
GO:0042127 Regulation of cell proliferation 23.04 0.86 0.71 7.97 0.87 0.71
GO:0042981 Regulation of apoptotic process 22.99 0.82 0.83 4.23 0.86 0.83
GO:0030334 Regulation of cell migration 17.90 0.81 0.05 4.70 0.72 0.76
GO:0030155 Regulation of cell adhesion 15.23 0.88 0.05 9.09 0.86 0.05
by cooperative involvement of multiple STATs with IRFs and/or
NF-κB.
Based on the previous studies, transcription of genes
containing STAT-, ISRE- and NF-κB-binding sites in their
promoter regions are under the cooperative regulation by
extracellular stimuli activating STATs, IRFs and NF-κB, such as
IFNγ, IFNα and TNFα, IL-1β or LPS (60–68). In general it is
believed that in immune cells, but also in vascular cells, multiple
inflammatory stimuli culminate in gene expression that requires
cooperation of STATs with IRFs and/or NF-κB (69). They are
responsible for promoting type I immune actions associated with
host-defense mechanisms against viral and bacterial infections
and excessive immune responses (70) at the basis of different
diseases, including CVDs. This correlates with our recent data
mining studies of atherosclerotic plaque transcriptomes. In this
study we performed detailed promoter analysis of differentially
expressed inflammatory genes in coronary and carotid plaques
and predicted cooperative involvement of NF-κB, STATs, and
IRFs (on ISRE, GAS, ISRE/GAS, ISRE/NF-κB, or GAS/NF-
κB binding sites) (71). Combined with our findings here, this
suggests strong inhibitory potential of C01L_F03, STATTIC,
and STX-0119 toward vascular inflammation and vascular
dysfunction.
The fact that among the 159 genes that were commonly
inhibited by C01L_F03, STATTIC and STX-0119 were multiple
chemokines and adhesion molecules, prompted us to investigate
the effect of a multi-STAT inhibitory strategy on IFNγ+LPS
dependent ECs migration and leukocyte adhesion to ECs. The
endothelial scratch wound (migration) assay has been described
as a simple and well-developed method to measure cell migration
in vitro (37), which reflects vascular and immune cell migration
during atherosclerosis. In addition, pathological angiogenesis of
the vessel wall is a consistent feature of atherosclerotic plaque
development and progression of the disease (72). Indeed, a
significant decrease in IFNγ+LPS-induced “wound healing” of
scratched ECs could be detected in the presence of C01L_F03,
STATTIC, and STX-0119 (Figure 9). Interestingly a subset
of C01L_F03, STATTIC and STX-0119 inhibited chemokines,
including CXCL9, CXCL10, CCL7, CCL8, CCL3L3, CCL5, and
CCRL2 (Table 5), has been reported to be increased in cells from
the vasculature. Also, transcriptional regulation of a number of
these genes in response to IFNγ and LPS in various cell types was
shown to involve multiple STATs, IRFs and or NF-κB (10, 71).
This coincides with our results here, but also with our recently
published data, in which elevated expression of the chemokines
CXCL9 and CXCL10 mirrored pSTAT1 levels in VSMCs and
ECs of human atherosclerotic plaques (10). Moreover, it was
proved that chemokines cooperate in leukocyte recruitment to
the injured artery during vascular remodeling (73–75) and as
such are involved in the pathogenesis of atherosclerosis. Our
observation that C01L_F03, STATTIC, and STX-0119 were also
able to significantly inhibit IFNγ-and LPS-dependent expression
of VCAM1 and ICAM1 (Figures 7, 8, Table 5, Table S1) as
well as dramatically reduce adhesion of leukocytes to ECs
under dynamic flow conditions (Figure 10), is in line with a
prominent role for both adhesion molecules in these phenomena
(59). Moreover, the transcriptional regulation of both ICAM1
and VCAM1 has shown to depend on several transcription
factors, including multiple STATs, IRFs, and NF-κB (59, 62, 76).
This could provide an explanation for the potent inhibitory
effect of C01L_F03, STATTIC, and STX-0119 on IFNγ+LPS-
induced adhesion of leukocytes to ECs, however we cannot
exclude the possibility that other adhesion molecules may also
be involved.
Finally, a multi-STAT inhibitory strategy was tested for
the potential to inhibit IFNγ+LPS induced impairment of
mesenteric artery contractility (Figure 11). Previously, we
observed that the signal integration between IFNγ and LPS in
mesenteric artery segments resulted in impaired contractility
(Figure 11A). This finding overlapped with a dramatic increase
in VSMC-specific expression of Nos2 (10), which is associated
with progression of atherosclerosis by participating in vascular
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dysfunction (77, 78). Now we prove for the first time that
C01L_F03, STATTIC, and STX-0119 are able to protect
against IFNγ and LPS induced impairment of mesenteric
artery contractility, likely by inhibiting Nos2 expression. The
transcriptional regulation of Nos2 in response to IFNγ and
LPS also has shown to depend on several transcription factors,
including STATs, IRFs, and NF-κB (61, 79).
STATTIC as well as STX-0119 have shown to increase the
apoptotic rate of a variety of cancer cell lines in vitro and in
tumors in vivo, in a STAT3-dependent manner. In our studies,
STATTIC and STX-0119, but also C01L_F03 exhibited cytotoxic
effects at the highest used concentrations. It is possible that
this cell death is mediated by inhibiting the anti-apoptotic
effects of STAT3. However, at lower concentrations at which
all three inhibitors potently inhibited STAT-dependent pro-
inflammatory and pro-atherogenic gene expression, this cell
death was not visible. Surprisingly, in the mesenteric artery
contractility experiments STATTIC and STX-0119 could only be
used in the nM range, without causing IFNγ+LPS-independent
impairment of vessel function and integrity. This is a thousand
fold less as in the wound healing and adhesion assay and could
point to a greater sensitivity of STATTIC and STX-0119 in vivo
as compared to in vitro.
In agreement with literature, targeting the STAT3 pathway
is an upcoming therapeutic approach in the treatment of a
rising number of inflammatory or proliferative diseases, like
myelofibrosis, myeloproliferative disorders, rheumatoid arthritis
and colitis ulcerosa also has a modulating effect on vascular
cell function. Several FDA-approved indirect STAT3 inhibitors
(Ruxolitinib: JAK1/2-inhibition; Tocilizumab: IL-6 receptor
antibody; Tofacitinib: pan-JAK inhibition) as well as currently
tested known drugs in clinical trials for CVDs treatment
(Sirukumab: IL-6 binding antibody; Baricitinib: JAK1/JAK2
inhibitor), predict the use of STAT3-inhibiting clinical strategies
in the near future (80). Recently, Johnson et al. for the
first time showed that STATTIC and S3I-201 protect against
AngII-induced oxidative stress, endothelial dysfunction, and
hypertension in mice (81). Because AngII promotes vascular
disease in the presence of multiple cardiovascular risk factors,
the authors suggested that selective targeting of STAT3 might
have substantial therapeutic potential. However, as S3I-201 and
STATTIC are not STAT3-specific (16), an additional role of other
STATs like STAT1 cannot be ruled out (82–85).
A large number of independent studies confirm the potency
of STATTIC as a direct STAT3 inhibitor and support its utility
in combating tumor cells. These studies demonstrate the potent
anticancer activities of STATTIC, including activity against
glioma cell migration on three-dimensional nanofiber scaffolds
(86), colon cancer-initiating cells (87), and against outgrowth of
breast cancer cells in an ex vivo model (88), and extend to in
vivo activity of STATTIC in a mouse xenograft model for head
and neck squamous cell carcinoma (89). Likewise, STX-0119 also
demonstrated potent antitumor effects in vivo in SCC3-bearing
nude mice in a STAT3-dependent manner (14). With their ability
to function as multi-STAT inhibitors, like C01L_F03, they could
additionally act as potent inhibitors of vascular inflammation in
atherosclerosis.
In conclusion, our STAT-inhibitory studies of C01L_F03,
STATTIC and STX-0119 and our previous revelation of STAT
cross-binding of a pre-selection of known STAT3 inhibitors in
combination with the literature, collectively provide evidence for
a novel class of multi-STAT inhibitory compounds that target
cooperative involvement of multiple STATs with NF-κB and/or
IRFs (on ISRE, GAS, ISRE/GAS, ISRE/NF-κB, or GAS/NF-κB
binding sites) in the regulation of crucial pro-inflammatory and
pro-atherogenic target genes (7). Based on this we propose their
potential as a potent clinical application in CVDs apart from their
established role in cancer treatment and prevention. It should be
noted that the primary aim of our study was to test our novel
comparative in silico docking STAT-inhibitor selection strategy
and offer support for the possibility of using a multi-STAT
inhibitory approach in the context of vascular inflammation.
However, our future studies will be dedicated to optimize our
selection strategy and identify new STAT inhibitors with higher
potency and bioavailability. Further testing and optimizing of
already available non-specific STAT inhibitors like STATTIC,
i.e., by chemical modification, may also be a promising avenue.
In this respect it is also important to consider that STATs are
essential factors to maintain normal homeostasis in many body
organs and tissues. Consequently, for the treatment of single
atherosclerotic lesions and to prevent systemic effects on other
STATs, a local, “targeted” application with negligible systemic
side effects might be a favorable scenario. Finally, it is important
to emphasize that IL-10 and IL-6 produced by macrophages
in the atherosclerotic plaque both regulate STAT3, yet generate
different cellular responses. IL-6 is primarily a pro-inflammatory
cytokine, whereas IL-10 generates a strong anti-inflammatory
response. IL-6 and IL-10 each bind to their cognate receptor,
leading to STAT3 phosphorylation, nuclear localization, and
a cytokine-specific gene activation pattern. Thus, within the
same cell type STAT3 can be pro- and anti-inflammatory (90,
91). When responding to certain stimuli such as inflammatory
mediators or microbial products, macrophages have the ability
to be polarized into M1 and M2 subtypes. M1 macrophages
express low levels of IL-10, M2 macrophages express abundant
IL-10 and can both be detected in atherosclerotic lesions. A
macrophage phenotypic switch from M2 to M1 occurs with
lesion progression and M1 macrophages dominate over M2
macrophages in the rupture-prone shoulder regions of the
plaque, whereas M2 polarized cells are found in stable plaques
(91). Current strategies of STAT3 inhibition do not consider
IL-10 action. Thus, for the anti-atherosclerotic treatment with
Statinibs to be most effective a treatment strategy should be
considered during the stages were theM1 phenotype is dominant
over the M2 phenotype, which correlates with low IL-10 levels
and during which activation of STAT3 by IL-6 shifts to pro-
inflammatory responses.
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